1. Home
  2. STTK vs TSE Comparison

STTK vs TSE Comparison

Compare STTK & TSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STTK
  • TSE
  • Stock Information
  • Founded
  • STTK 2016
  • TSE 2010
  • Country
  • STTK United States
  • TSE United States
  • Employees
  • STTK N/A
  • TSE N/A
  • Industry
  • STTK Biotechnology: Pharmaceutical Preparations
  • TSE Major Chemicals
  • Sector
  • STTK Health Care
  • TSE Industrials
  • Exchange
  • STTK Nasdaq
  • TSE Nasdaq
  • Market Cap
  • STTK 83.8M
  • TSE 83.1M
  • IPO Year
  • STTK 2020
  • TSE 2014
  • Fundamental
  • Price
  • STTK $2.14
  • TSE $2.53
  • Analyst Decision
  • STTK Hold
  • TSE
  • Analyst Count
  • STTK 6
  • TSE 0
  • Target Price
  • STTK $2.67
  • TSE N/A
  • AVG Volume (30 Days)
  • STTK 1.5M
  • TSE 219.5K
  • Earning Date
  • STTK 11-13-2025
  • TSE 11-05-2025
  • Dividend Yield
  • STTK N/A
  • TSE 1.57%
  • EPS Growth
  • STTK N/A
  • TSE N/A
  • EPS
  • STTK N/A
  • TSE N/A
  • Revenue
  • STTK $2,997,000.00
  • TSE $3,258,300,000.00
  • Revenue This Year
  • STTK N/A
  • TSE N/A
  • Revenue Next Year
  • STTK N/A
  • TSE $4.84
  • P/E Ratio
  • STTK N/A
  • TSE N/A
  • Revenue Growth
  • STTK N/A
  • TSE N/A
  • 52 Week Low
  • STTK $0.69
  • TSE $1.90
  • 52 Week High
  • STTK $3.95
  • TSE $7.05
  • Technical
  • Relative Strength Index (RSI)
  • STTK 58.93
  • TSE 52.87
  • Support Level
  • STTK N/A
  • TSE $2.34
  • Resistance Level
  • STTK $2.01
  • TSE $2.55
  • Average True Range (ATR)
  • STTK 0.21
  • TSE 0.14
  • MACD
  • STTK 0.01
  • TSE 0.03
  • Stochastic Oscillator
  • STTK 99.53
  • TSE 91.38

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About TSE Trinseo PLC

Trinseo PLC is a materials company and manufacturer of latex and plastics products. The company's operating segments include Latex Binders, Americas Styrenics, Engineered Materials, and Polymer Solutions. Maximum revenue is generated from its Polymer Solutions segment, which consists of various polymers, the majority of which are for automotive, building, and construction applications. The product offerings of this segment include ABS, styrene-acrylonitrile, polystyrene, and polycarbonate products, which are marketed through brands like Magnum and Styron. Geographically, the company generates maximum revenue from Europe, followed by the United States, Asia-Pacific, and the Rest of the world.

Share on Social Networks: